Hot Healthcare Technology Companies To Watch In Right Now

Gen. Casey leaves a meeting with Iraqi army officers in Baghdad, February 2007.

(Fortune) I was recently asked to address the students of the University of North Carolina's Kenan-Flagler Business School on "Leading in a VUCA World." I must admit that as soon as I got off the call with the school's executive director, I went to the computer and Googled "VUCA." Ten seconds later it was clear why the acronym was vaguely familiar to me: It was a term coined by the U.S. Army War College in the early 1990s to describe what the world would be like after the Soviet Union's collapse: volatile, uncertain, complex, and ambiguous.

In reality, VUCA has never been more relevant, for the military and for business. I experienced VUCA environments in Bosnia (1996), in Kosovo (2000), and in Iraq (2004-07). Leading grew progressively more difficult in those conflicts, with Iraq unquestionably the toughest. I believe that my experiences leading in those environments can benefit business leaders.

Hot Building Product Stocks To Watch For 2015: Nordic American Tanker Ltd (NAT)

Nordic American Tankers Limited is an international tanker company. As of December 31, 2011, the Company owned 20 Suezmax tankers. The Company�� vessels include Nordic Harrier, Nordic Hawk, Nordic Hunter, Nordic Voyager, Nordic Freedom, Nordic Fighter, Nordic Discovery, Nordic Saturn, Nordic Jupiter, Nordic Apollo and Nordic Moon. Its vessels also include Nordic Cosmos, Nordic Sprite, Nordic Grace, Nordic Mistral, Nordic Passat, Nordic Vega, Nordic Breeze, Nordic Aurora and Nordic Zenith. In September 2011, the Company acquired the vessel, Nordic Aurora. It chartered all of its vessels in the spot market pursuant to a cooperative arrangement with Gemini Tankers LLC until November 24, 2011. In November 2011, the Orion Tankers pool was established with Orion Tankers Ltd. as pool manager and its vessels were transferred from the Gemini Tankers LLC arrangement to the Orion Tankers pool. On December 17, 2012, the Company acquired 100% interest in Scandic American Shipping Ltd. Advisors' Opinion:

• [By Eric Volkman]

  Nordic American Tankers (NYSE: NAT  ) is presenting a calm sea to its stockholders by keeping its upcoming dividend level with the previous payout. The company has declared a distribution of $0.16 per share of its common stock for its Q1, which its expects to hand out "on or about" May 14. It expects that the record date will be April 30.

Hot Healthcare Technology Companies To Watch In Right Now: Tutor Perini Corporation(TPC)

Tutor Perini Corporation, together with its subsidiaries, provides diversified general contracting, construction management, and design-build services to private clients and public agencies worldwide. It operates in three segments: Civil, Building, and Management Services. The Civil segment involves in public works construction, and the repair, replacement, and reconstruction of infrastructure. This segment?s civil contracting services include construction and rehabilitation of highways, bridges, mass transit systems, and wastewater treatment facilities. The Building segment provides services to various specialized building markets for private and public works clients, such as the hospitality and gaming, transportation, healthcare, municipal offices, sports and entertainment, education, correctional facilities, biotech, pharmaceutical, industrial and high-tech markets, electrical and mechanical, plumbing, and HVAC services. The Management Services Segment offers diversifie d construction and design-build services to the United States military and government agencies, surety companies, and multi-national corporations in the United States and internationally. This segment also provides rapid response and contract completion services; and management or general contracting services to fulfill the contractual and financial obligations of the surety on notification from the surety of a contractor bond default. The company was founded in 1894 and is headquartered in Sylmar, California.

Advisors' Opinion:

• [By Travis Hoium]

  What: Shares of construction company Tutor Perini (NYSE: TPC  ) jumped 12% today after the company released earnings.

  So what: First quarter revenue was up 9%, to $992.9 million, and earnings nearly quadrupled, to $0.31 per share. Wall Street expected revenue to be $983.2 million and earnings of just $0.24, so investors were pleasantly surprised by the results.�

• [By Rich Smith]

  Following up on the news that it's the likely winner of a $985 million contract to design the Madera-to-Fresno segment�of California's new high-speed railway, civil engineering firm Tutor Perini� (NYSE: TPC  ) announced Tuesday that it's scored a second major contract win.

• [By Ben Levisohn]

  Shares of Harsco have gained 4.7% to $26.43 today at 1:16 p.m., outpacing other construction & engineering companies. Dycom (DY) has advanced 0.5% to $30, KBR Inc. (KBR) has ticked up 0.1% to $33.03, Worthington Industries�(WOR) has risen 2.8% to $38.85�and Tutor Perini (TPC) has rallied 3.6% to $22.46.

• [By Rich Smith]

  On Wednesday, civil engineering firm Tutor Perini Corp. (NYSE: TPC  ) said the California High-Speed Rail Authority has identified its $985 million bid to design the initial Madera-to-Fresno segment�of California's high-speed railway as the "apparent best value" of all bids received.

Hot Healthcare Technology Companies To Watch In Right Now: HCA Holdings Inc (HCA)

HCA Holdings, Inc. (HCA), incorporated in January 1990, is a holding company whose affiliates owns and operates hospitals and related health care entities. HCA is a health care services companies in the United States. At December 31, 2011, it operated 163 hospitals, comprised of 157 general, acute care hospitals; five psychiatric hospitals, and one rehabilitation hospital. In addition, it operated 108 freestanding surgery centers. Its operations are structured into three geographically organized groups: the National, Southwest and Central Groups. At December 31, 2011, the National Group includes 64 hospitals located in Florida, South Carolina, southern Georgia, Alaska, California, Nevada, Utah and Idaho, the Southwest Group includes 46 hospitals located in Colorado, Texas, Oklahoma and the Wichita, Kansas market, and the Central Group includes 47 hospitals located in Louisiana, Indiana, Kentucky, Tennessee, Virginia, New Hampshire, northern Georgia and the Kansas City market. The Company also operates six hospitals in England, and these facilities are included in the Corporate and other group. Its facilities are located in 20 states and England. During October 2011, the Company completed its acquisition of the Colorado Health Foundation�� (Foundation).In December 2011, it sold Palmyra Medical Center in Albany, Ga.

The Company�� general, acute care hospitals typically provide a range of services to accommodate such medical specialties as internal medicine, general surgery, cardiology, oncology, neurosurgery, orthopedics and obstetrics, as well as diagnostic and emergency services. Outpatient and ancillary health care services are provided by its general, acute care hospitals, freestanding surgery centers, diagnostic centers and rehabilitation facilities. Its psychiatric hospitals provide a full range of mental health care services through inpatient, partial hospitalization and outpatient settings.

The Company owns, manages or operates hospitals; freestanding surgery cente! rs; diagnostic and imaging centers; radiation and oncology therapy centers; rehabilitation and physical therapy centers, and various other facilities. At December 31, 2011, it owned and operated 157 general, acute care hospitals with 40,988 licensed beds. Most of its general, acute care hospitals provide medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic services and emergency services. The general, acute care hospitals also provide outpatient services such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology and physical therapy. At December 31, 2011, it operated five psychiatric hospitals with 506 licensed beds. Its psychiatric hospitals provide therapeutic programs including child, adolescent and adult psychiatric care, adult and adolescent alcohol and drug abuse treatment and counseling.

The Company also operates outpatient health care facilities, which include freestanding ambulatory surgery centers (ASCs), freestanding emergency care facilities, diagnostic and imaging centers, comprehensive outpatient rehabilitation and physical therapy centers, outpatient radiation and oncology therapy centers and various other facilities. Most of its ASCs are operated through partnerships or limited liability companies, with majority ownership of each partnership or Limited Liability Company typically held by a general partner or subsidiary that is an affiliate of HCA. Certain of its affiliates provide a variety of management services to its health care facilities, including patient safety programs; ethics and compliance programs; national supply contracts; equipment purchasing and leasing contracts; accounting, financial and clinical systems; governmental reimbursement assistance; construction planning and coordination; information technology systems and solutions; legal counsel; human resources services; and internal audit services. Under the Medicare program, it receives reimbursement under a prospective payment system (PPS) ! for gener! al, acute care hospital inpatient services.

Advisors' Opinion:

• [By Johanna Bennett]

  In a note published today, Goldman Sachs analysts Robert Boroujerdi, John Marshall, Michael Chanin and Krag Gregory say not much gfear�has been�priced into put options for either the S&P 500 or stocks with higher exposure to government spending. As a result, they suggest one of the following hedging strategies:

  Buy the optimal SPX puts to hedge a 5% down-move: Buying a November 1650 put on the S&P 500 index costs 1.2% and Goldman estimates a 2.7-to-1 payout if the index falls 5% by mid-October. Beware of government exposure: The firm tracks a basket of more than 100 companies that derive at least 20% of their revenue from the government. Though the list includes defense contractors and tech giant, more than half of the names are health-care companies, including Amgen (AMGN), HCA (HCA) and UnitedHealth Group (UNH). Buy puts on stocks with high government exposure: November puts on government-exposed names cost 2.4% on average (5% out of the money strike)

Hot Healthcare Technology Companies To Watch In Right Now: Sealed Air Corporation(SEE)

Sealed Air Corporation, through its subsidiaries, provides food safety and security, facility hygiene, and product protection solutions worldwide. Its Food Packaging segment provides shrink bags and vacuum packaging products; packaging materials for cook-in applications; laminated and coextruded rollstock packaging materials used in thermoforming and form, fill, and seal applications; and associated packaging equipment and systems, including bag loaders, dispensers, and vacuum chamber systems. The company?s Food Solutions segment offers case-ready packaging offerings; ready meals packaging technologies; vertical pouch packaging solutions for packaging flowable food products; foam and plastic trays; absorbent products for food packaging; and related packaging equipment, including vacuum chamber systems. Its Protective Packaging segment provides air cellular packaging materials; polyolefin performance shrink films for product display; shrink packaging equipment systems; pol yurethane foam packaging systems that provide protective packaging; lightweight and tear-resistant mailers and bags; inflatable packaging systems; paper cushioning systems that include recycled paper and automated dispensing equipment; paper packaging products; and suspension and retention packaging products. The company?s Diversey Segment offers a range of products and services, such as kitchen cleaning products; food and beverage and manufacturing and processing products; floor care products and systems; restroom care and other housekeeping products; and laundry products, as well as consulting services. Sealed Air Corporation also provides specialty materials products to fabricators and manufacturers; and medical applications products and solutions to medical device manufacturers and pharmaceutical companies. The company markets its products primarily under the Bubble Wrap, Cryovac, and Diversey brands. Sealed Air Corporation was founded in 1960 and is headquartered in El mwood Park, New Jersey.

Advisors' Opinion:

• [By Lee Jackson]

  Basic Materials: Sealed Air Corp. (NYSE: SEE) is top pick at other firms that we cover on Wall Street as well. Credit Suisse believes that following the recent (October) management change at the company, Sealed Air will significantly improve its profitability and cash flows while also deleveraging its sizable debt load, with both of these things driving significant shareholder value. The price target for the stock is posted at $36. The Thomson/First Call estimate is at $33. Investors are paid a 1.9% dividend. Credit Suisse is the high target on Wall Street and would represent a 31% gain for investors. The stock closed Tuesday at $27.48.

• [By Ben Levisohn]

  On the upside, Sealed Air (SEE) has gained 8.4% to $30.90 after it said it earned 39 cents share, beating forecasts for 34 cents, and offered strong guidance. Gilead Sciences (GILD) has risen 4.3% to $72.50 after it reported a profit of 52 cents, beating forecasts for 48 cents.

Hot Healthcare Technology Companies To Watch In Right Now: The Cushing MLP Total Return Fund(SRV)

Cushing MLP Total Return Fund is a closed-end mutual fund launched by Swank Capital, LLC. The fund is managed by Swank Energy Income Advisors L.P. It invests in the public equity and fixed income markets across the globe with a focus in United States. The fund typically invests in MLPs, Other Natural Resource Companies, and global commodities. It primarily invests in the securities of MLPs, other equity securities, debt securities, and securities of non-U.S. issuers employing a fundamental analysis. Cushing MLP Total Return Fund was formed on May 23, 2007 and is domiciled in Dallas.

Advisors' Opinion:

• [By Robert Rapier]

  As I write this, Tortoise Pipeline and Energy (NYSE: TTP) trades at a discount of 15.1 percent to its underlying assets, while at the other end of the spectrum Cushing MLP Total Return Fund (NYSE: SRV) trades at a 17.4 percent premium. The average MLP closed-end fund listed trades at a 4.9 percent discount, which is perhaps reasonable given the loss of certain tax advantages and the fact that management fees will eat into returns.

• [By Robert Rapier]

  As I write this, Tortoise Pipeline and Energy (NYSE: TTP) trades at a discount of 15.1 percent to its underlying assets, while at the other end of the spectrum Cushing MLP Total Return Fund (NYSE: SRV) trades at a 17.4 percent premium. The average MLP closed-end fund listed trades at a 4.9 percent discount, which is perhaps reasonable given the loss of certain tax advantages and the fact that management fees will eat into returns.

Hot Healthcare Technology Companies To Watch In Right Now: Roche Holding AG (RHHBY)

Roche Holding AG is a Switzerland-based pharmaceuticals and diagnostics company. The Company belongs to the Roche Group that operates through numerous subsidiaries and associated companies located around the world. The Company�� products and services cover every stage of the healthcare process, from identifying disease susceptibilities and testing for disease in at-risk populations to prevention, diagnosis, therapy and treatment monitoring. Roche operates through two divisions: Pharmaceuticals and Diagnostics. Within the Pharmaceuticals Division there are three sub-divisions: Roche Pharmaceuticals, Genentech and Chugai. The Company�� Diagnostics Division includes five sub-divisions: Applied Science, Diabetes Care, Molecular Diagnostics, Tissue Diagnosis and Professional Diagnostics. Its activities are structured into six geographical segments: North America; Asia-Pacific; Western Europe; Latin America; Central and Eastern Europe, Middle East and Africa (CEMAI), and Japan. In March 2009, the Company completed the acquisition of Genentech, Inc. In March 2010, the Company acquired assets from BioMicro Systems for all products associated with the Roche NimbleGen microarray workflow.

During the year ended December 31, 2008, the Company Pharmaceuticals Division marketing gained approvals for its rheumatoid arthritis medicine Actemra/RoActemra in Japan, Switzerland and the European Union. In 2008, the division initiated 12 new phase III projects in, including clinical trials of the compounds pertuzumab, for breast cancer; taspoglutide, for type two diabetes, and dalcetrapib, for cardiovascular risk reduction. As of December 31, 2008, the Pharmaceuticals Division filed 11 major new marketing applications and gained 13 major regulatory approvals. At the beginning of 2009, the division�� research and development pipeline comprised 120 clinical projects, including 62 new molecular entities (NMEs) and 58 additional indications. Forty NMEs are in phase I, 16 in phase II and six in phase III or f! iled for regulatory review.

In 2008, Roche Pharmaceuticals signed a total of 57 new agreements including seven product transactions and 43 research and technology collaborations. In May 2008, Roche acquired Piramed Limited, a UK company with therapeutic research programmes targeting the PI3-kinase pathway in oncology and inflammatory disease. In June 2008, signed licensing agreement with ThromboGenics and BioInvent for their jointly developed anticancer agent TB-403 (R7334). In September, 2008, the Company acquired Mirus Bio Corporation active in the field of ribonucleic acid interference (RNAi) delivery and completed the acquisition of ARIUS Research Inc., which has a antibody platform that identifies and selects antibodies based on their functional ability to affect disease. S Research Inc. In January 2009, Roche acquired Memory Pharmaceuticals, which develops drug candidates for the treatment of debilitating central nervous system disorders such as Alzheimer�� disease and schizophrenia.

Pharmaceuticals

Within Pharmaceuticals division, the Company is engaged in the provision of drugs the areas of oncology, anemia, cardiovascular diseases, central nervous system, infectious diseases, inflammatory and autoimmune diseases, metabolic disorders, cancer, transplantation and virology. The products offered by Roche�� Pharmaceuticals division include MabThera/Rituxan, Herceptin, Avastin, Tamiflu, CellCept, NeoRecormon, Epogin, Pegasys, Tarceva, Xeloda, Bonviva, Boniva, Lucentis, Tamiflu, Xolair, Valcyte, Cymevene, Xenical, Pulmozyme, Nutropin, Neutrogin, Rocephin, Activase, TNKase and Madopar. The products offered by the Pharmaceuticals division are sold in seven geographic regions: North America; Asia-Pacific; Western Europe; Latin America; Central and Eastern Europe, Middle East and Africa (CEMAI), and Japan.

Diagnostics

Roche�� Diagnostics Division is a supplier of in vitro diagnostics (IVDs). Its products are used to test body fluids a! nd tissue! samples to obtain information for the purpose of preventing, diagnosing, treating and monitoring disease. The Company has business areas five within the diagnostics division: Professional Diagnostics, Diabetes Care, Tissue Diagnostics, Molecular Diagnostics and Applied Science. Roche�� Diagnostics division provides IVD services, including centralized laboratory testing and point-of-care diagnostics to molecular diagnostics and diabetes self management. In addition, it supplies research tools to life scientists.

Roche Professional Diagnostics supplies instrument systems, tests, software and services. It provides point-of-care testing products to support clinical decision-making close to the patient, in doctors��offices, emergency rooms and other primary and specialty care settings. Twelve Serum Work Area assays were rolled out during the year ended December 31, 2008, across Europe and in other markets. New assays included the Elecsys anti-TSH receptor antibody assay for the diagnosis of Graves��disease the Elecsys anti-CCP antibody assay, a test to aid the diagnosis of rheumatoid arthritis, and the Roche Cystatin C clinical chemistry test for early detection of impaired kidney function, among others. Roche Diabetes Care�� products portfolio covers the entire diabetes self-management spectrum, from glucose monitoring to insulin delivery, as well as monitoring systems with integrated lancets and test strips software for storing and analyzing data. Roche Tissue Diagnostics develops and manufactures medical diagnostic instruments and reagent systems that provide automation technology for use in the diagnosis and prognosis of cancer and infectious disease. In 2008 Roche Tissue Diagnostics launched ofhe Bench- Mark Ultra, a system that performs immunohistochemistry and in situ hybridisation testing simultaneously on a single continuous and random access platform. Roche Molecular Diagnostics develops and commercializes diagnostic and blood screening platforms and tests based on Roche�� ! real-time! polymerase chain reaction (PCR) technology. Applied Science business area supplies a specific reagents and test kits for use in life sciences encompassing biology, biotechnology ,medical research, as well as disease areas like cancer and virology. Applied Science�� business area product portfolio includes such sequencing systems as LightCycler 480, LightCycler 480 II, GS FLX Titanium. In addition, Applied Science offers xCELLigence cell analyzer.

Advisors' Opinion:

• [By Dimitra DeFotis]

  There are two cancer vaccines on the market: Provenge, a prostate-cancer treatment from Seattle-based Dendreon�(DNDN), and Yervoy, a melanoma treatment from Bristol-Myers Squibb�(BMY), according to Dow Jones Newswires. In May, Roche�Holding (RHHBY) said its experimental cancer vaccine, called MPDL3280A, shrank tumors in 21% of 140 patients participating in a trial. It is now performing tests in lung cancer patients.